University of Delaware
University of Delaware sponsors 106 registered US clinical trials on ClinicalTrials.gov, 24 of them currently recruiting, and 72 completed. 8 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Parkinson Disease, with 4 trials.
Trial Pipeline
106 total, page 3 of 3
Mental Health Services for Toddlers in Foster Care
NCT01261806
Effectiveness of a Parent Training Program for Parents of Children Adopted Internationally
NCT00816621
The Role of COX-2 Inhibition in Salt Sensitivity of Blood Pressure
NCT00624559
Long-term Use of Proton Pump Inhibitors May Cause Vitamin B12 Deficiency in the Institutionalized Elderly
NCT00843453
Mental Health Services for Foster and Adopted Children
NCT00056303
Wedged Orthoses and Knee Osteoarthritis
NCT00420147
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 3 | 1 |
| Phase 4 | 7 |
Therapeutic Areas
What the Pipeline for University of Delaware Shows
According to the ClinicalTrials.gov registry, University of Delaware is linked to 106 US clinical trials across every stage of research activity. Of those, 24 studies are currently recruiting, about 23% of the sponsor's indexed portfolio, and 72 are already marked complete, representing roughly 68% of the total.
The phase mix for University of Delaware reports 8 late-stage studies (Phase 3 and Phase 4 combined) and 3 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for University of Delaware is Parkinson Disease with 4 linked trials, and 9 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.